Anixa Biosciences (ANIX) - Rentabilitas dodolan reged

Simbol resmi perusahaan Anixa Biosciences (ANIX)

Anixa Biosciences is engaged in a patent battle within the high-risk vaccine race, leveraging streamlined component supply chains. On GURU.Markets, the gross margin reflects profit dynamics net of costs, with the indicator standing at 0.00. Proprietary developments in the treatment of female cancers create barriers to entry, transforming future products into high-yield assets.

Tingkat bathi miturut bathi reged anixa.com (ANIX): kanggo periode 04.07.2022 - 20.11.2026

Rincian metrik keuangan lan pasar anixa.com (ANIX)

- kuotasi saiki lan rata-rata prakiraan nilai:
- indikator kapitalisasi pasar:
Analisis dhasar perusahaan:ANIX Anixa Biosciences
Produk dadi Anixa Biosciences, Inc.

Automation of breast cancer drug synthesis at Anixa Biosciences (ANIX) reduces costs, yet medical oversight expenses in clinics directly impact the cost of goods sold. The gross margin as a percentage of revenue reflects the efficiency of this balance, measuring the percentage of funds remaining after covering direct production costs, which allows investors to assess the fundamental profitability of the business through historical peaks and troughs.